Protagonist Therapeutics (PTGX) Receivables - Other (2017 - 2025)
Protagonist Therapeutics (PTGX) has disclosed Receivables - Other for 9 consecutive years, with $4.4 million as the latest value for Q4 2025.
- Quarterly Receivables - Other fell 97.35% to $4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, down 97.35% year-over-year, with the annual reading at $4.4 million for FY2025, 97.35% down from the prior year.
- Receivables - Other hit $4.4 million in Q4 2025 for Protagonist Therapeutics, down from $4.6 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $165.0 million in Q4 2024 to a low of $39000.0 in Q2 2023.
- Historically, Receivables - Other has averaged $15.2 million across 5 years, with a median of $3.3 million in 2021.
- Biggest five-year swings in Receivables - Other: plummeted 99.8% in 2023 and later skyrocketed 64353.12% in 2024.
- Year by year, Receivables - Other stood at $1.6 million in 2021, then plummeted by 97.32% to $42000.0 in 2022, then skyrocketed by 509.52% to $256000.0 in 2023, then surged by 64353.12% to $165.0 million in 2024, then plummeted by 97.35% to $4.4 million in 2025.
- Business Quant data shows Receivables - Other for PTGX at $4.4 million in Q4 2025, $4.6 million in Q3 2025, and $4.5 million in Q2 2025.